A5057855208- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Global Cancer Incidence and Screening
- Occupational and environmental lung diseases
- Economic and Financial Impacts of Cancer
- COVID-19 and healthcare impacts
- Glioma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Synthesis and biological activity
- Pain Management and Opioid Use
- Head and Neck Cancer Studies
- Prostate Cancer Treatment and Research
- COVID-19 Clinical Research Studies
- Meningioma and schwannoma management
- Oral health in cancer treatment
- Radiation Dose and Imaging
- Ovarian cancer diagnosis and treatment
- Health Systems, Economic Evaluations, Quality of Life
Ospedale Santa Maria della Misericordia di Udine
2019-2022
Ospedale di Santo Spirito
2022
University of Udine
2016-2020
Azienda Ospedaliero Universitaria Maggiore della Carita
2014-2015
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2014-2015
Ewing's sarcoma (ES) is an aggressive tumour that may present with skeletal and extraskeletal forms. The form rarely encountered in the head neck region extremely rare sinonasal tract. This case report of a ES ethmoid sinus intracranial orbital extension 33-year-old male patient who presented anosmia, epistaxis, reduction visual acuity left eye headache. On otorhinolaryngological clinical examination biopsy via flexible endoscope, lesion was misdiagnosed as carcinoma. subsequent magnetic...
Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns treatment sequences. Patients & methods: is a retrospective multicenter Italian observational including consecutive Caucasian referred between 2014 2018. Results: 167...
A multidisciplinary team meeting (MDM) approach in breast cancer (BC) management is a standard of care. One the roles MDMs to identify best diagnostic and therapeutic strategies for patients (pts) with new diagnosis early BC. The purpose this study was define whether there an agreement between planned program (i.e., MDMs-based decision) that actually applied. In addition, explored factors associated discordance.
Even if now we have available the weapon of vaccination against SARS-CoV-2, patients with cancer remains a very frail population in which frequently immunologic response to may be impaired. In this setting, SARS-CoV-2 infection screening retains great value. However, there are still limited data on feasibility and efficacy combined procedures assess prevalence (including asymptomatic cases) outpatients undergoing antineoplastic therapy.From May 1, 2020, June 15, during first wave pandemic,...
(35%) and photosensitivity reactions (25%), grade 1 or 2 side effects as per the Common Terminology Criteria for Adverse Events (CTCAE). Elevated liver enzymes were documented in close to 10% of treated patients no prolongation QTc interval, cardiac arrhythmias, keratoacanthoma squamous cell carcinoma reported. Dosing’s modification has been required three patients: two have discontinued treatment they resumed at 720 mg/bid while one patient 480 mg/bid. Nobody needed stop due unacceptable...
e21639 Background: Immunotherapy has changed the paradigm on NSCLC treatment. No widespread and reproducible predictive biomarkers have been established. We analyzed how PrC could affect ICI outcomes. Methods: conducted a retrospective observational study all patients (pts) treated with (nivolumab or atezolizumab pembrolizumab) in our institution from 2015 to 2018 followed until January 2020. All pts had received at least one PrC. recorded clinical features of both before after Results: A...
Neurofibromatosis type 2 (NF2) is a dominantly inherited genetic condition. Unlike patients with sporadic tumours, NF2 often have multiple meningiomas, acoustic neurinomas and ependymomas. The multiplicity of tumours make surgery radiation therapy for all impracticable. In effect, bilateral are the hallmark this disease these cause progressive hearing loss in most patients. Neovascularization necessary tumour growth driven by produced angiogenic factors such as vascular endothelial factor...
1554 Background: Our prospective non-randomized ATOM002 study showed that LDCT screening of asbestos-exposed subjects can identify LC at an earlier, potentially more curable, stage than chest radiographs (CXR) (Fasola et al, The Oncologist 2007). cohort was selected from enrolled in a surveillance program with annual CXR for asbestos exposed workers the Monfalcone Occupational Health Unit, Friuli Venezia Giulia (FVG) region, Italy. Here, we report mortality program, comparing outcomes...
e21601 Background: Despite great improvements in lung cancer (LC) treatment over the last years, significant toxicities are still observed that may lead to unscheduled access oncology clinic as well hospital admission. Furthermore, LC patients (pts) frequently require emergency medical care due acute unbearable symptoms and life-threatening conditions. Our study aimed describe magnitude of this phenomenon pts identify risk factors affecting number outcome accesses. Methods: We...
<h3>Introduction/Background</h3> Patients (pts) with ovarian cancer experiencing a platinum-sensitive (PS) recurrence are generally re-exposed to platinum agents (PCT). The addition of bevacizumab (BEV) or PARP inhibitors (PARPi) as concomitant and/or maintenance therapy has shown improve progression free survival (PFS). In the absence direct comparisons coming from randomized trials (RCTs), we have performed network meta-analysis evaluate differences in terms efficacy between BEV and PARPi...
Abstract Background: The combination of endocrine therapy with the cyclin-dependent kinases 4/6 inhibitor palbociclib was proven to be effective for treatment hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (MBC). Although generally well tolerated, delays and dose reductions are frequently observed palbociclib, mainly due severe neutropenia. Predictors palbociclib-related toxicities still unknown, as clinical relevance its relative intensity (RDI). Henceforth, this...
e14143 Background: The rapid development of immunotherapy (IO) has transformed the cancer therapy landscape with growing impact on oncology workload. Given few data this topic, we conducted a study to estimate shift in workload generated by any new metastatic patient treated IO and referred Oncology Department Academic Cancer Center Udine, Italy, within 12 months first consultation. Methods: We collected from our “Data Warehouse” electronic accountability system all diagnosis between...